Sublingual vs Buccal Ketamine Troche Placement

When a ketamine troche is prescribed, the label usually instructs the patient to place it "under the tongue" or "in the cheek" — but the difference between sublingual and buccal placement is often glossed over. Both routes use the oral mucosa as the absorption surface, and both reach similar bioavailability when hold time is maintained. The choice between them is mostly about comfort, taste tolerance, and how each route fits a particular patient's session protocol.

This guide breaks down what each route actually means, where the absorption physiology overlaps, and how to decide which placement might work better for a given patient. It is general education, not a prescribing protocol.

Defining Sublingual and Buccal Routes

Sublingual placement positions the troche under the tongue, against the floor of the mouth. The mucosa here is thin, richly vascularized, and exposed to high saliva flow from the sublingual and submandibular glands.

Buccal placement positions the troche between the inner cheek and the gum, usually toward the upper back of the mouth. The mucosa is slightly thicker than sublingual tissue, and the area sees less saliva flow, which can extend dissolution time.

Absorption: Where the Routes Overlap

Both routes bypass first-pass hepatic metabolism for the portion of the dose that absorbs through the mucosa. Published bioavailability estimates for sublingual ketamine fall in the 20 to 30 percent range. Buccal absorption is in a similar range. The portion of the dose that is eventually swallowed yields the much lower 16 to 20 percent gut-route bioavailability.

What this means in practice: route choice is less impactful than hold time. A patient who holds buccal placement for the full prescribed window will absorb more drug than a patient who swallows a sublingual dose at 5 minutes.

Where the Routes Diverge

Even with similar absorption ceilings, the two routes feel different to the patient and have practical trade-offs:

• Taste exposure. Sublingual placement releases the dissolved solution directly onto the floor of the mouth and the tongue, which makes the characteristic bitter taste more pronounced. Buccal placement pockets the solution away from the tongue, blunting taste.
• Gag reflex. Buccal placement is usually more comfortable for patients with strong gag reflex or who find saliva pooling unpleasant.
• Dissolution speed. Sublingual placement tends to dissolve faster. Buccal placement is slower, which suits longer hold-time protocols.
• Localized numbness. Both routes can cause transient tongue or cheek numbness; rotating placement between sessions can reduce this.
• Speech and saliva control. Buccal placement allows clearer speech during the hold window, which can matter for patients who need to communicate with a sitter.

Choosing a Placement: Practical Factors

Patients are often best served by trying both routes across a small number of sessions, with their prescriber's awareness, and noting which one produces a more tolerable experience at equivalent absorption. Factors to weigh:

1. Taste tolerance. Buccal placement helps if the troche flavor is the main barrier to completing hold time.
2. Dry mouth medications. Patients on anticholinergic or SSRI medications that reduce saliva may prefer sublingual placement, where flow is naturally higher.
3. Hold time goals. Longer prescribed hold windows pair well with buccal placement.
4. Oral health. Active mouth sores, dental work sites, or denture wearers may need to favor whichever route avoids the affected area.
5. Dose splitting. If a protocol uses two smaller pieces during a session, alternating placement can help spread mucosal exposure.

Taste Management Across Both Routes

Compounded ketamine troches typically carry a bitter or chemical taste that some flavoring systems only partly mask. Strategies that work for either route include rinsing with cool water beforehand, sucking on a small piece of ice to slightly numb the tongue, brushing teeth at least 30 minutes prior, and using a saline rinse after the hold window has fully elapsed. Avoid acidic juices and strongly flavored foods immediately before dosing — they can amplify the bitter aftertaste.

Patients dosing with split troches sometimes pair the second piece with a different placement to limit cumulative taste exposure. Hard sugar-free mints after the hold window can also help with the lingering aftertaste, though they should never be used during the hold itself.

What About Dose Splitting?

Some at-home protocols call for a single troche split into two pieces — for example, half held at the start of the session, with the remaining half added 20 to 40 minutes later if effects are too mild. Both pieces can be placed in the same location, or alternated between sublingual and buccal pockets to spread mucosal exposure and avoid taste fatigue. Always split only as directed by the prescriber, since compounded troches are not guaranteed to have uniform drug distribution and uneven halves can produce uneven absorption.

Placement Comparison at a Glance

Safety Notes and Contraindications

Ketamine is contraindicated or used with extreme caution in uncontrolled hypertension, unstable cardiovascular disease, untreated hyperthyroidism, active psychotic disorders, severe liver impairment, recent stroke, increased intracranial pressure, and certain bladder conditions. Pregnancy is a contraindication outside of specific clinical settings. Patients with active oral infections, severe periodontal disease, mouth ulcers, or recent oral surgery should consult their prescriber about whether to delay sessions or temporarily adjust placement.

Whichever route is chosen, never swallow the dissolved solution before the full hold window prescribed on the label. If unusual irritation, persistent numbness beyond a session, or any allergic reaction develops, stop dosing and contact your provider.